Stockscreener 앱 받기
12.44
6.23%
0.73
시간 외 거래:
12.39
-0.05
-0.40%
전일 마감가:
$11.71
열려 있는:
$11.73
하루 거래량:
779.72K
Relative Volume:
0.81
시가총액:
$975.05M
수익:
$54.55M
순이익/손실:
$-193.57M
주가수익비율:
-4.3045
EPS:
-2.89
순현금흐름:
$-181.86M
1주 성능:
+7.06%
1개월 성능:
+2.47%
6개월 성능:
-36.24%
1년 성능:
-34.28%
1일 변동 폭
$11.46
$12.90
1주일 범위
$11.34
$12.90
52주 변동 폭
$8.18
$29.56
누릭스 테라퓨틱스 Stock (NRIX) Company Profile
명칭
Nurix Therapeutics Inc
전화
(415) 660-5320
주소
1700 OWENS STREET, SUITE 205, SAN FRANCISCO
NRIX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
NRIX
Nurix Therapeutics Inc
|
12.44 | 975.05M | 54.55M | -193.57M | -181.86M | -2.89 |
|
VRTX
Vertex Pharmaceuticals Inc
|
457.03 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
547.74 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
329.77 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
545.11 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
244.32 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
누릭스 테라퓨틱스 Stock (NRIX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-03-17 | 개시 | Leerink Partners | Market Perform |
| 2024-12-10 | 개시 | BTIG Research | Buy |
| 2024-12-06 | 개시 | BMO Capital Markets | Outperform |
| 2024-10-24 | 개시 | UBS | Buy |
| 2024-10-11 | 개시 | Jefferies | Buy |
| 2024-09-06 | 재개 | Robert W. Baird | Outperform |
| 2024-07-31 | 개시 | Truist | Buy |
| 2023-06-26 | 재개 | Oppenheimer | Outperform |
| 2023-03-09 | 개시 | Barclays | Overweight |
| 2023-02-28 | 개시 | Oppenheimer | Outperform |
| 2022-10-11 | 개시 | Morgan Stanley | Equal-Weight |
| 2022-05-31 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2022-02-10 | 개시 | Wells Fargo | Equal Weight |
| 2021-12-29 | 개시 | H.C. Wainwright | Buy |
| 2021-10-14 | 개시 | SVB Leerink | Outperform |
| 2021-06-04 | 재개 | Robert W. Baird | Outperform |
| 2021-04-30 | 재개 | Piper Sandler | Overweight |
| 2021-04-30 | 개시 | RBC Capital Mkts | Outperform |
| 2021-04-14 | 개시 | Berenberg | Buy |
| 2020-11-19 | 개시 | Robert W. Baird | Outperform |
| 2020-08-18 | 개시 | JP Morgan | Overweight |
| 2020-08-18 | 개시 | Needham | Buy |
| 2020-08-18 | 개시 | Piper Sandler | Overweight |
| 2020-08-18 | 개시 | Stifel | Buy |
모두보기
누릭스 테라퓨틱스 주식(NRIX)의 최신 뉴스
Analysts Conflicted on These Healthcare Names: Align Tech (ALGN), Nurix Therapeutics (NRIX) and Thermo Fisher (TMO) - The Globe and Mail
Nurix Therapeutics (NRIX) to Participate in Key Oppenheimer Conf - GuruFocus
Nurix Therapeutics (NRIX) to Participate in Key Oppenheimer Conference | NRIX Stock News - GuruFocus
NuCana (NRIX) to Participate in Key Oppenheimer Conference | NRIX Stock News - GuruFocus
(NRIX) Investment Analysis - news.stocktradersdaily.com
Nurix Therapeutics (NASDAQ:NRIX) Trading Down 5.9%Here's What Happened - MarketBeat
Nurix Therapeutics’ SWOT analysis: promising BTK degrader stock faces challenges - Investing.com Nigeria
Nurix Therapeutics’ SWOT analysis: promising BTK degrader stock faces challenges By Investing.com - Investing.com South Africa
Nurix Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Nurix Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | NRIX Stock News - GuruFocus
Nurix Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - MarketScreener
Nurix Therapeutics, Inc. (NASDAQ:NRIX) Receives $30.18 Average PT from Brokerages - MarketBeat
Nurix Therapeutics (NRIX) Shares Dip After Trial Update on Bexob - GuruFocus
Nurix stock drops on new trial data for lead drug (NRIX:NASDAQ) - Seeking Alpha
Transcript : Nurix Therapeutics, Inc.Special Call - MarketScreener
Nurix Therapeutics Announces Positive Phase 1 Trial Results - TipRanks
NRIX: Promising Data from Nurix's Bexobrutideg Clinical Trial | - GuruFocus
NRIX: Promising Data from Nurix's Bexobrutideg Clinical Trial | NRIX Stock News - GuruFocus
Nurix Therapeutics Presents Updated Positive Data Demonstrating Durable, Deepening Responses in Ongoing Clinical Trial of Bexobrutideg (NX-5948) Monotherapy in Patients with Relapsed/Refractory Chroni - GuruFocus
Nurix Therapeutics Presents Updated Positive Data Demonstrating Durable, Deepening Responses in Ongoing Clinical Trial of Bexobrutideg (NX-5948) Monotherapy in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) and Waldenströ - The Manila Times
Breakthrough: Nurix Cancer Drug Achieves Complete Response in Hard-to-Treat Blood Cancers, New Trial Data Shows - Stock Titan
Nurix Therapeutics reports new KLHDC2 inhibitors - BioWorld MedTech
Truist Financial Sticks to Its Buy Rating for Nurix Therapeutics (NRIX) - The Globe and Mail
Nurix Therapeutics, Inc. to Discuss Data from the Ongoing Phase 1 Clinical Trial of Bexobrutideg Being Presented At the 30Th European Hematology Association Congress - marketscreener.com
Nurix Therapeutics to Host a Webcast Conference Call to Discuss - GuruFocus
Nurix Therapeutics to Host a Webcast Conference Call to Discuss Data from the Ongoing Phase 1 Clinical Trial of Bexobrutideg (NX-5948) Being Presented at the 30th European Hematology Association Congress (EHA2025) - The Manila Times
Nurix Therapeutics to Host a Webcast Conference Call to Discuss Data from the Ongoing Phase 1 Clinical Trial of Bexobrutideg (NX-5948) Being Presented at the 30th European Hematology Association Congr - GuruFocus
Nurix Therapeutics to Host Webcast on Phase 1 Clinical Trial Data for Bexobrutideg (NX-5948) at EHA2025 - Nasdaq
Nurix Therapeutics to Host a Webcast Conference Call to Discuss Data from the Ongoing Phase 1 ... - Bluefield Daily Telegraph
Bexobrutideg Phase 1 Trial Shows Promise in Blood Cancer Treatment at EHA Congress | NRIX Stock News - Stock Titan
Nurix Therapeutics (NASDAQ:NRIX) Shares Gap UpHere's Why - MarketBeat
Stifel Maintains Buy Rating on Nurix (NRIX) Stock - MSN
Nurix Therapeutics (NRIX) Moves 14.2% Higher: Will This Strength Last? - MSN
Nurix Therapeutics, Inc. (NASDAQ:NRIX) Shares Bought by Two Sigma Investments LP - MarketBeat
(NRIX) On The My Stocks Page - news.stocktradersdaily.com
Nurix Therapeutics, Inc. (NASDAQ:NRIX) Stock Position Reduced by Nuveen Asset Management LLC - MarketBeat
Sanofi exercises option to license STAT6 program from Nurix collaboration - BioWorld MedTech
Nurix Therapeutics Stock Climbs as Sanofi Extends License for STAT6 - marketscreener.com
Sanofi Exercises Exclusive License for Nurix Therapeutics' STAT6 Program - marketscreener.com
Sanofi Exercises License Extension Option To Nurix'S Stat6 Program - marketscreener.com
Sanofi Expands Rare Immunology Portfolio With Blueprint Buyout - Benzinga
Sanofi Licenses Nurix's STAT6 Program, Enhancing Drug Collaborat - GuruFocus
Sanofi Licenses Nurix's STAT6 Program, Enhancing Drug Collaboration | NRIX Stock News - GuruFocus
Sanofi Exercises License Extension Option to Nurix's STAT6 Program | NRIX Stock News - GuruFocus
Nurix secures additional $15 million from Sanofi license deal - Investing.com
Nurix Therapeutics Secures $15 Million License Extension from Sanofi for STAT6 Program - Nasdaq
Sanofi Bets Big on Nurix: $465M Deal for Revolutionary Inflammation Drug That Could Transform Asthma Treatment - Stock Titan
Nurix Therapeutics, Inc. (NASDAQ:NRIX) Shares Bought by Wellington Management Group LLP - MarketBeat
Nurix Therapeutics (NASDAQ:NRIX) Trading Up 3.9%Time to Buy? - MarketBeat
Millennium Management LLC Has $7.99 Million Stock Position in Nurix Therapeutics, Inc. (NASDAQ:NRIX) - MarketBeat
Twinbeech Capital LP Sells 35,683 Shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX) - MarketBeat
누릭스 테라퓨틱스 (NRIX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.45%
0.86%
자본화:
|
볼륨(24시간):